Knight Therapeutics NIKTIMVO® Receives Brazilian Regulatory Approval
Knight Therapeutics Inc. has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab) for the treatment of chronic graft-versus-host disease.
Story updates
11:41:47 AM UTC
SquawkNews
Knight Therapeutics received expedited ANVISA approval for NIKTIMVO (axatilimab) to treat chronic GVHD after failure of at least two prior systemic therapies in patients 6+ years and ≥40 kg in Brazil.Material DetailsContext by AI AnalystThis is a mid-cycle expansion of Knight’s LATAM oncology/rare…